You searched for Sydney Lupkin - Page 2 of 4 - KFF Health News

Secretive ‘Rebate Trap’ Keeps Generic Drugs For Diabetes And Other Ills Out Of Reach

By Jay Hancock and Sydney Lupkin January 18, 2019 KFF Health News Original

Patients are often forced into using brand names because drug formularies favor them over cheaper competitors.

Big Pharma Gave Money To Patient Advocacy Groups Opposing Medicare Changes

By Sydney Lupkin and Elizabeth Lucas and Victoria Knight March 4, 2019 KFF Health News Original

A KHN database shows that $58 million flowed from drugmakers to patient groups running national ads.

Unwitting Patients, Copycat Comments Play Hidden Role In Federal Rule-Making

By Sarah Jane Tribble September 11, 2018 KFF Health News Original

As HHS decided to cut $1.6 billion in drug payments to hospitals, it weighed thousands of comments generated by a pharmaceutical-funded advocacy group.

When Medicine Makes Patients Sicker

By Sydney Lupkin Photos by Heidi de Marco January 4, 2019 KFF Health News Original

The Food and Drug Administration is supposed to inspect all factories, foreign and domestic, that produce drugs for the U.S. market. But a KHN review of thousands of FDA documents — inspection records, recalls, warning letters and lawsuits — reveals how drugs that are poorly manufactured or contaminated can reach consumers.

Government Investigation Finds Flaws In the FDA’s Orphan Drug Program

By Sarah Jane Tribble and Sydney Lupkin November 30, 2018 KFF Health News Original

A probe by the Government Accountability Office cites breakdowns in the Food and Drug Administration program that approves drugs for rare diseases.

Mining A New Data Set To Pinpoint Critical Staffing Issues In Skilled Nursing Facilities

By Jordan Rau July 30, 2018 KFF Health News Original

Low staffing is a root cause of many injuries in nursing homes. Kaiser Health News senior correspondent Jordan Rau explains how he connected the dots between manpower and risk at facilities nationwide, using a federal tool known as the Payroll-Based Journal.

Drugmakers Funnel Millions To Lawmakers; A Few Dozen Get $100,000-Plus

By Emmarie Huetteman and Sydney Lupkin October 16, 2018 KFF Health News Original

Drugmakers’ contributions to lawmakers have peaked as surging drug prices emerge as a hot-button political issue. In the past decade, Congress has received nearly $79 million from 68 pharma PACs, run by employees of companies that make drugs treating everything from cancer to erectile dysfunction.

Pfizer Settles Kickback Case Related To Copay Assistance For $24M

By Sydney Lupkin May 24, 2018 KFF Health News Original

The drugmaker agreed to a settlement with the Justice Department over allegations that it funneled copay assistance money through a foundation to Medicare patients.

Drugmakers Blamed For Blocking Generics Have Jacked Up Prices And Cost U.S. Billions

By Sydney Lupkin May 23, 2018 KFF Health News Original

The Trump administration is shaming brand-name drugmakers who refuse to sell samples so generics can be made from their products.

‘Pharma Bro’ Shkreli Is In Prison, But Daraprim’s Price Is Still High

By Shefali Luthra May 4, 2018 KFF Health News Original

The saga of Martin Shkreli and Turing Pharmaceuticals focused a lot of attention on prescription drug prices, but no reversal of the exponential price increases for the lifesaving drug Daraprim resulted. The story offers an object lesson into the interworkings of the pharmaceutical market.

Patients Overpay For Prescriptions 23% Of The Time, Analysis Shows

By Sydney Lupkin March 13, 2018 KFF Health News Original

Researchers at the University of Southern California analyzed millions of prescriptions and concluded that close to a quarter paid copays that exceeded the cost of the drugs.

Big Pharma Greets Hundreds Of Ex-Federal Workers At The ‘Revolving Door’

By Sydney Lupkin January 25, 2018 KFF Health News Original

A KHN data analysis finds that the door of opportunities connecting Capitol Hill, the federal government and the drug industry likely spins in Big Pharma’s favor.

States Strive To Curb Costs For A Crucial — But Exorbitant — Hemophilia Treatment

By Barbara Feder Ostrov Photos by Heidi de Marco March 6, 2018 KFF Health News Original

Saving the lives of people with the bleeding disorder can require high doses of expensive blood-clotting factor. Taxpayers foot much of the bill as manufacturers profit enormously.

FDA Chief Says He’s Open To Rethinking Incentives On Orphan Drugs

By Sarah Jane Tribble December 22, 2017 KFF Health News Original

The FDA’s Scott Gottlieb says the agency is focused on the big picture, and he wants to know why pharma churns out drugs for some rare diseases but not for others.

Patient Advocacy Groups Take In Millions From Drugmakers. Is There A Payback?

By Emily Kopp and Sydney Lupkin and Elizabeth Lucas April 6, 2018 KFF Health News Original

Kaiser Health News launches “Pre$cription for Power,” a groundbreaking database to expose Big Pharma’s ties to patient groups.

Reporter’s Notebook: In Health Care, A Good Price (Or Any Price) Is Hard To Find

By Jenny Gold September 14, 2017 KFF Health News Original

Not only are health prices hidden, industry players are contractually obligated to keep them secret. That’s why answering a simple question — how much does it cost to have a baby in Mountain View, Calif.? — became a journalistic quest.

Climbing Cost Of Decades-Old Drugs Threatens To Break Medicaid Bank

By Sydney Lupkin August 14, 2017 KFF Health News Original

Medicaid spent billions more in 2016 than the year before on decades-old prescription drugs, including many generics, a Kaiser Health News data analysis shows.

Everyone Says We Must Control Exorbitant Drug Prices. So, Why Don’t We?

By Jay Hancock September 25, 2017 KFF Health News Original

Any momentum to address prescription drug costs has been lost amid rancorous debates over replacing Obamacare and stalled by roadblocks erected via lobbying and industry cash.

Right After Trump Blamed High Drug Prices On Campaign Cash, Drugmakers Gave More

By Sydney Lupkin and Elizabeth Lucas September 27, 2017 KFF Health News Original

At a political rally in March, President Donald Trump said drug prices are “outrageous” and blamed campaign contributions. Drugmakers funneled nearly $280,000 to Congress the very next day.

Guess Who Pays The Price When Hospital Giants Hire Your Private Practitioner?

By Jenny Gold September 8, 2017 KFF Health News Original

Gobbling up doctors’ independent practices is lucrative for hospital systems — but not necessarily a good deal for the physicians or consumers, critics say. Northern California is a case in point.

Filter Results

More From KFF Health News